These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 203832

  • 1. [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
    Schwartzkopff W, Zschiedrich M.
    Med Klin; 1978 Feb 17; 73(7):231-9. PubMed ID: 203832
    [Abstract] [Full Text] [Related]

  • 2. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Feb 17; 33(5):776-9. PubMed ID: 6683558
    [Abstract] [Full Text] [Related]

  • 3. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R, Müller A, Klose G, Middelhoff G, Augustin J, Haase W, Greten H.
    MMW Munch Med Wochenschr; 1978 Apr 14; 120(15):525-8. PubMed ID: 206826
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination of clofibrate and inositol nicotinate (author's transl)].
    Wilke H, Frahm H.
    Dtsch Med Wochenschr; 1976 Mar 12; 101(11):401-5. PubMed ID: 1253701
    [Abstract] [Full Text] [Related]

  • 5. [The problem of type changes in hyperlipoproteinemia (type IIb, IV, V) under clofibrate and m-inositol nicotinate therapy].
    Schwartzkopff W, Zschiedrich M.
    Verh Dtsch Ges Inn Med; 1976 Mar 12; 82 Pt 1():825-9. PubMed ID: 196436
    [No Abstract] [Full Text] [Related]

  • 6. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
    Wechsler JG, Hutt V, Klör HU, Ditschuneit H.
    Artery; 1980 Mar 12; 8(6):519-29. PubMed ID: 7259531
    [Abstract] [Full Text] [Related]

  • 7. [The effect of a lipid-reducing clofibrate-inositolnicotinate combination compared to clofibrate. A double-blind study].
    Schäfer B, Kluthe R.
    Med Welt; 1975 Apr 04; 26(14):655-63. PubMed ID: 1099394
    [No Abstract] [Full Text] [Related]

  • 8. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L, Olsson AG, Rössner S, Carlson LA.
    Postgrad Med J; 1975 Apr 04; 51(8):suppl 76-81. PubMed ID: 215986
    [Abstract] [Full Text] [Related]

  • 9. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W, Kremer GJ, Müller D.
    MMW Munch Med Wochenschr; 1975 Oct 31; 117(44):1783-6. PubMed ID: 171564
    [Abstract] [Full Text] [Related]

  • 10. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L, Olsson AG, Rössner S, Carlson LA.
    Postgrad Med J; 1975 Oct 31; 51(8):76-81. PubMed ID: 176639
    [No Abstract] [Full Text] [Related]

  • 11. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Artery; 1980 Oct 31; 8(2):113-9. PubMed ID: 7458676
    [Abstract] [Full Text] [Related]

  • 12. [The effect of etofibrate on serum cholesterol and triglycerides (author's transl)].
    Dimroth H.
    Med Klin; 1979 Jun 01; 74(22):875-6. PubMed ID: 470785
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
    Koschinsky T, Gries FA, Schwandt P, Weisweiler P, Hansen W, Nijssen J, Beckmann R.
    MMW Munch Med Wochenschr; 1977 May 20; 119(20):701-4. PubMed ID: 195201
    [Abstract] [Full Text] [Related]

  • 14. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
    Weisweiler P, Schwandt P.
    Verh Dtsch Ges Inn Med; 1977 May 20; 83():398-401. PubMed ID: 206058
    [No Abstract] [Full Text] [Related]

  • 15. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 May 20; 33(12):1682-4. PubMed ID: 6686774
    [Abstract] [Full Text] [Related]

  • 16. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
    Rouffy J, Dreux C, Goussault Y, Dakkak R, Renson FJ.
    Arzneimittelforschung; 1976 May 20; 26(5):901-6. PubMed ID: 183788
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
    Koschinsky T, Lenhard P, Gries FA, Vogelberg KH, Wolfram G, Lang PD, Vollmar J.
    Med Klin; 1977 Sep 23; 72(38):1537-43. PubMed ID: 904549
    [Abstract] [Full Text] [Related]

  • 18. [Clinical testing of a combination of clofibrate and beta-pyridylcarbinol in an unusual dosis relation].
    Mann S, Maisenbacher HJ.
    Z Allgemeinmed; 1975 Aug 31; 51(24):1066-71. PubMed ID: 1101545
    [No Abstract] [Full Text] [Related]

  • 19. [Effects of various modes of therapy on the fatty acid spectrum in hyperlipoproteinemia].
    Reuter W.
    Z Gesamte Inn Med; 1977 Jul 01; 32(13):203-5. PubMed ID: 930182
    [Abstract] [Full Text] [Related]

  • 20. [Clofibrate therapy--the status quo].
    Reuter W.
    Z Gesamte Inn Med; 1982 Jan 15; 37(2):59-63. PubMed ID: 7080553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.